MEDI 7814

Drug Profile

MEDI 7814

Alternative Names: MEDI7814

Latest Information Update: 10 Apr 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action Complement C5a inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 21 Mar 2013 Discontinued - Phase-I for Chronic obstructive pulmonary disease (in volunteers) in USA (IV)
  • 09 Jul 2012 MedImmune completes enrolment in its phase I trial in Healthy volunteers in USA (NCT01544361)
  • 29 Feb 2012 Phase-I clinical trials in Chronic obstructive pulmonary disease (in healthy volunteers) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top